Health care products business ill-fated Kang Pui Group direct or difficult to break

High profits are often accompanied by high risk. In CCTV "3 15" party exposure Zhejiang Connaught State Health Products Co., Ltd. (Connobon) suspected of violating the production of June Bao Kang cod liver oil, causing the industry uproar. Then other media reports Connobon as a subsidiary of Kang-Bei, in the face of rumors, Cambe quickly clear relations. March 16, Kang-PUI group in its official online statement, admitted to have a stake in the Connobon, but in December 2012, it has been held Connobon all the shares transferred to the company's management, and the change of business registration procedures for shareholders, has no relationship at present. A sudden storm may be difficult to the health of the shellfish group or listed companies to affect, but in recent years, health care products business always to Cambe trouble, has made Kang-PUI group's health care strategy clouded. The former subsidiary was suspected to have violated the original name Cambe Health Products Co., Ltd., not only the majority of senior executives for the former employees of the group, even the vice chairman of the group, Wu Zhong, also served as a health products company director. In the case of cod liver oil incident, Connobon director Chong refused the "China Business newspaper" reporter's interview, and the company's securities representative also said: "At present, the two companies have no relationship." "The reporter inspected the annual report of Kang-eun-pui, found that Connobon was indeed founded by the group in 2006, registered capital of 16 million yuan, at the end of 2012, before the withdrawal of the group, the former name Cambe Health Products Co., Ltd. (hereinafter referred to as" Health products Company "), Not only did most senior executives serve as former employees of the Wu Zhong group, but even the vice chairman of the Kang Pui Group was also a director of the Health products company. Public data show that Connobon was founded in November 2006, with a registered capital of 16 million yuan, funded by the Kang-PUI group. Main business focus on the mother and infant products, positioning "plant source, functional, middle and high-end", the current operation has "June Bao Kang" "Extract Fu Li," "Excellent AH" three major brands. Connobon is not only a state-level High-tech enterprises, or the Baby Industry Association vice President Enterprise. By the end of December 2012, health-products companies had been separated from the Cambe with executive teams. After the company changed its name to Zhejiang Connaught State Health Products Co., Ltd., there will be several venture investment enterprises to come. Connobon the latest industrial and commercial data show that its shareholders mainly include management shares, Hangzhou Yin Nbond Enterprise Management Consulting Co., Ltd., Zhejiang Sea-Peng Investment Consulting Co., Ltd., Zhejiang Shin-Hai venture Capital Partnership (limited Partnership), Zhejiang Zhe Shangli Venture Capital Partnership (limited Partnership). Among them, the latter three are all Zhejiang business Venture investment subsidiaries and venture capital fund. A reporter received a "rapid development of maternal and child health products Company equity financing 20 million Yuan" project financing report shows: "The company 2012 revenue scale is expected to be 40 million yuan, forecast, 2013-2015 years, the company's revenue growth to 70 million yuan, 120 million yuan, 180 million yuan." In order to meet the financial requirements of the continuous expansion of scale, the company plans to 2012 seasonsOpen a round of financing, the introduction of external strategic investment, the framework of the project: the introduction of 20 million yuan capital, accounting for the issuance of 20% of the company's equity. "And the project's contact person is just one of Connobon's shareholders, Chong, March 19, the reporter called Chong's mobile phone, its ignorance, not familiar with the structure of the company's products refused to be interviewed. Media reports said that, in fact, Connobon chairman and the boss of the company is relative relations, at the end of 2012, the Connobon is also want to let the independent development of a better, for the future listing to prepare. However, make Connobon difficult to control the difficult problem is, Connobon can only be the identity of food enterprises, aquatic processing, confectionery products, bee products production. And in the National Food and Drug Administration of the Web page, the production of cod liver oil, such as health products enterprises or pharmaceutical enterprises, no traces of Connobon. In addition, cod liver oil is not produced as food, so the FDA's website does not have any food companies to produce cod liver oil health food. June 2013 Hu Gangliang in CCTV's "health and nutrition food business leaders Meeting", the Nutrition and health food is divided into two categories, a large category need to do licensing management, another may be used for filing system, may be more effective methods. Hu Gangliang seems to want to use this proposal to broaden access standards in the health food sector. However, Hu Gangliang's proposal was not approved by regulators. The "3 15" exposure Connobon illegal production cod liver oil, its a big sticking point is that Connobon has not produced cod liver oil and other health food production qualification.　Even Connobon Beijing petitioners proved that cod liver oil can be used as health food for infants and children, it is difficult for their own illegal production off duty. The fate of health care products business Health care products business after several twists and turns, embarked on a transition to direct marketing business model. The impact of the Connobon cod-liver oil incident on the Kang-bei group is still difficult to assess, but the development of health care products in the group has not been successful. At the end of 2012, just handed the health products company's Kang-bei group took over the listed company's health care products business. Due to weak performance growth, Kang-pui shares of health care products business at the end of 2012 completely dumped to the major shareholder of the Kang-eun-pui group. December 27, 2012 night notice, Kang-Pui shares to the company's controlling shareholder, Kang Pui Group, a wholly-owned subsidiary of Health Care products company 100% Equity. As one of the oldest assets of the company, the health-care-products firm was founded in 1996. Has Beibei children's products and Yongbong capsules two major product lines, including Beibei blood Bao, Beibei appetizer Treasure, Beibei Sundance, Yuan Bang capsule for Zhejiang province, is a well-known brand, is the key health food production enterprises in Zhejiang province. However, then WTF, as the original products such as Yongbong, Beibei, such as weak growth, new products do not keep up with the problem, health care products business has been a serious impact on the business development of listed companies. Analysis of the industry, in addition to business losses, health care products business legal risk is also its shares give up health care products business one of the reasons, health care productsIndustry has a blind area of supervision, resulting in the risk of corporate law and regulation increased. There have been media reports, at the end of 2011, Kang-PUI health care products company without obtaining certification and government approval, began in its production of two products at the same time labeled "China Organic Product certification" and "National Geographic indications protection products" two kinds of signs, illegal acts lasted nearly two years, illegal production and sales volume of more than 20,000 boxes (package). Kang-PUI group took over the health care products company, the health care products business because of the difficult marketing costs, product competitiveness decline, and so on, operating still hard, loss more than tens of millions of dollars. In early 2013, the company decided to let its health care products business into the field of direct marketing. But throughout, the group has not been tight-lipped about its direct sales business. In November 2013, after several denials, Zhejiang Kang-PUI Group Medical Health Products Co., Ltd. finally issued a notice, said that it has submitted to the national business sector related materials, formal application for the "Direct selling business license." mentioned Cambe Direct marketing, there is a person has to say, that is the new marketing company Kang-PUI group-Zhejiang Kang full home New Marketing Co., Ltd. General manager Lo Yongliang. Lo Yongliang was Amway's Emerald (Amway dealer-level salutation), leaving Amway in 1998, after several rounds, to Xiamen Jin Ri Jia Pharmaceutical Co., Ltd. (hereinafter referred to as "Xiamen Jin Ri Jia") as the general manager. Xiamen Jin Ri Jia in July 2011 to obtain a direct sales license, and the establishment of its direct marketing network, the outside world is often attributed to Lo Yongliang. Early last year, Lo Yongliang came to Cambe. In an interview with reporters, Lo Yongliang said that at present, Kang-Bei has not launched any direct sales business, the online Cambe in the recruitment of direct sales are not the truth. Cambe Health Care Products Co., Ltd. is already actively applying for direct sales licences, for when to obtain direct sales licences, Luo expressed unclear. However, there are references to the progress of the cards. May 2013, Sig pharmaceutical application for direct sales license issued by the Ministry of Commerce in the official online system, and after 8 months, 2014 years after the success of the pharmaceutical industry fancy, Cambe to take the card time is not too long. Lo Yongliang also said that at present, the new marketing company is creating mobile Internet business Platform, its positioning is to build a health industry platform Kang-PUI, wait until the success of the card, and then direct sales model to promote the development of the industrial platform. However, the traditional enterprises to set up direct sales enterprises to operate, there was no precedent, and similar to Cambe pharmaceutical companies Harbin drug shares may be worth learning. August 2006, Harbin Pharmaceutical Group began to apply for direct sales licence to the Ministry of Commerce, until August 2007 was finally approved. Harbin Medicine became the first domestic listed company to enter the direct sales business. After a year of preparation, Harbin Medicine officially announced the start of a direct trial operation on December 1, 2009. Harbin Medicine from Get direct licence to start business officially, the total investment 300 million yuan. Eventually, however, Harbin's shares had to stop selling in 2011. Today, Kang-PUI Group's health care products business after several twists and turns, embarked on a transition to direct marketing business model, the future if Kang-enBeschen brand Success, in addition to facing the quality of health products themselves, the red line in the field of direct marketing will also test the management level of the high levels of Kang-PUI group.